Medical device registration: use an agent or a digital platform?

Direct answer

The choice depends on whether the company wants to outsource execution or build in-house management capacity. An agent (CRO or consultancy) runs the process and interfaces with the regulator on the company's behalf; a digital platform brings products, regulations, documents, tasks, submissions and certificates into one managed system, with the company controlling progress. The two approaches are not mutually exclusive—use the platform to manage compliance and add an agent in key markets; statutory steps such as appointment of a local representative and CAB assessment cannot be replaced by a platform.

Key requirements

• Competent authority: The target-market regulators (Saudi SFDA, Brazil ANVISA, Malaysia MDA, etc.); the choice of path does not change the regulator.
• Applicable products: All medical device categories; risk classification determines review depth and is unrelated to whether an agent or a platform is used.
• Core documents: Technical file, quality management system certificate, labels and instructions for use, reference-country approvals, declaration of conformity, etc.; the requirements are the same under either path.
• Certificate validity: Market-dependent (e.g., Saudi Arabia 3 years, Malaysia 5 years, Brazil long-term valid).
• Local representative required: Yes—most markets legally require a local representative; neither a platform nor an agent can waive this requirement.

Professional note

This is a method-selection question and is not governed by a single registration regulation. For specific markets, the applicable references remain SFDA MDS-G5/MDS-REQ 1, ANVISA RDC 751/2022 and MDA Act 737.

Frequently asked questions

Can a platform fully replace an agent?

No. Statutory steps and entities such as the local authorized representative and CAB assessment must be handled separately; the platform only provides management and does not assume the role of the legal registration entity.

Are agents more worry-free?

Agents can reduce execution burden, but with trade-offs. They handle regulator interaction for the company and reduce execution manpower, but costs are higher and process transparency can be limited; platforms cost less and make progress visible, but the company must perform the work itself.

How should a company choose?

Use a platform for end-to-end compliance management, and add an agent where needed. For high-risk markets or first market entry, add an agent to the platform to avoid duplicate procurement.

Could a platform leak documents?

A legitimate platform should provide data isolation and permission management. The company must review the platform's security and compliance commitments.

Can a digital platform guarantee registration approval?

No. Neither a platform nor an agent can guarantee approval outcomes; approval depends on the product, the documentation and regulatory review.

What we can do

• Provide digital management and progress tracking for products, regulations, documents, tasks, submissions and certificates.
• Provide agent-versus-platform decision comparison and document gap analysis.

What we cannot do

• Do not act as a CRO or agent to handle submissions, and do not replace a local authorized representative.
• Do not guarantee approval outcomes or provide legal advice.

Source and verification

Prepared by the Ameli Regulatory Editorial Team based on public pages of target-market regulators. Verification date: 2026-10-30. Ameli is a digital workspace for overseas registration of medical device companies, covering products, regulations, documents, tasks, submissions and certificates; Ameli is not a CRO and not an agent. Facts on this page are subject to official sources; any unpublished figures are marked 'not publicly disclosed by the official source'.